ANI Pharmaceuticals, Inc. (ANIP) vs Ocular Therapeutix, Inc. (OCUL)
A side-by-side comparison of ANI Pharmaceuticals, Inc. and Ocular Therapeutix, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIP
ANI Pharmaceuticals, Inc.
$71.53HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
OCUL
Ocular Therapeutix, Inc.
$7.46HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
Total return — ANIP vs OCUL
growth of $100 · dividends reinvested · last 10yANIP +5.2% (+0.5%/yr)OCUL +5.8% (+0.6%/yr)OCUL compounded faster over this window
ANIP OCUL
ANIP vs OCUL: by the numbers
- •OCUL is the larger company ($1.63B vs $1.63B market cap).
- •ANIP is profitable (10.82% net margin) while OCUL runs a net loss (-579.10%).
- •ANIP grew revenue faster over the past five years (35.61% vs 10.03% CAGR).
Metrics side by side
Valuation
| Metric | ANIP | OCUL |
|---|---|---|
| P/E ratio | 15.45 | N/A |
| Forward P/E | 7.71 | N/A |
| P/S ratio | 1.66 | 31.39 |
| P/B ratio | 2.72 | 3.14 |
| EV / EBITDA | 6.76 | N/A |
Profitability
| Metric | ANIP | OCUL |
|---|---|---|
| Gross margin | 51.01% | 87.11% |
| Operating margin | 15.35% | -521.04% |
| Net margin | 10.82% | -579.10% |
| ROE | 17.72% | -57.97% |
| ROIC | 9.26% | -50.20% |
Growth (annualized)
| Metric | ANIP | OCUL |
|---|---|---|
| Revenue CAGR (5Y) | 35.61% | 10.03% |
| Total return CAGR (5Y) | 16.86% | -5.73% |
Frequently asked
- Which has grown faster, ANIP or OCUL?
- Over the past five years, ANIP grew revenue faster — ANIP at a 35.61% CAGR versus OCUL at 10.03%.
- Is ANIP or OCUL more profitable?
- ANIP runs the higher net margin — ANIP at 10.82% versus OCUL at -579.10%.
Go deeper
Dig into the metrics
ANI Pharmaceuticals P/E ratioANI Pharmaceuticals ROEOcular Therapeutix ROEANI Pharmaceuticals operating marginOcular Therapeutix operating marginANI Pharmaceuticals revenue growthOcular Therapeutix revenue growthANI Pharmaceuticals free cash flowOcular Therapeutix free cash flow
ANI Pharmaceuticals & Ocular Therapeutix appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.